Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Vandetanib and Sirolimus in Patients With Recurrent Glioblastoma

This study has been completed.
Brigham and Women's Hospital
Dana-Farber Cancer Institute
Information provided by (Responsible Party):
Tracy T. Batchelor, MD, Massachusetts General Hospital Identifier:
First received: January 9, 2009
Last updated: April 30, 2015
Last verified: April 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: February 2015
  Primary Completion Date: February 2015 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by Identifier (NCT Number):